Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 3/20 | 0.55 |
| ▸ | TERT | O14746 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 4/20 | 0.48 |
| ▸ | HTR2B | P41595 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TLR2 | O60603 | 2/20 | 0.43 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.42 |
| ▸ | CTSC | P53634 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL620066 | 1.00 | PRCP (0.55) | PRCPTERTHTR2CHTR2BKDM4E | |
| SCHEMBL8789170 | 1.00 | PRCP (0.55) | PRCPTERTHTR2CHTR2BKDM4E | |
| SCHEMBL6372058 | 0.95 | PRCP (0.50) | PRCPTERTHTR2CHTR2BKDM4E | |
| SCHEMBL30481218 | 0.93 | TERT (0.51) | PRCPTERTHTR2CHTR2BKDM4E | |
| SCHEMBL10788824 | 0.93 | TERT (0.51) | PRCPTERTHTR2CHTR2BKDM4E | |
| SCHEMBL31142126 | 0.93 | TERT (0.51) | PRCPTERTHTR2CHTR2BKDM4E | |
| SCHEMBL464682 | 0.93 | TERT (0.51) | PRCPTERTHTR2CHTR2BKDM4E | |
| Glycine SCHEMBL2933526 | 0.93 | PRCP (0.50) | PRCPTERTHTR2CHTR2BKDM4E | |
| SCHEMBL10788841 | 0.93 | TERT (0.51) | PRCPTERTHTR2CHTR2BKDM4E | |
| Trifluoroacetic Acid SCHEMBL19209820 | 0.91 | HTR2C (0.48) | PRCPTERTHTR2CHTR2BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 714 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4003288-B1 | COSMETIC COMPOSITION WITH COMBINED FILLER AND SKIN REGENERATIVE EFFECT | GIULIANI SPA (IT) | 2026-05-06 | — | — | EP | claimed |
| EP-4724610-A2 | HIGH THROUGHPUT SCREEN FOR GENETIC VARIANTS ASSOCIATED WITH SHORT STATURE | BioMarin Pharmaceutical Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260098072-A1 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | ENDEVICA BIO INC (US) | 2026-04-09 | — | — | US | claimed |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | SOCIETE DES PRODUITS NESTLE S.A. (CH) | 2026-03-24 | — | — | US | claimed |
| EP-4013453-B1 | HYDROPHOBIC PEPTIDE SALTS FOR EXTENDED RELEASE COMPOSITIONS | BIOMARIN PHARM INC (US) | 2026-03-04 | — | — | EP | claimed |
| EP-4679087-A1 | BIOMARKER AND USE THEREOF | MEIJI CO., LTD (JP) | 2026-01-14 | — | — | EP | claimed |
| US-12514906-B2 | Use of C-type natriuretic peptide variants to treat skeletal dysplasia | BIOMARIN PHARMACEUTICAL INC. (US) | 2026-01-06 | — | — | US | claimed |
| EP-4665374-A1 | METHODS OF PREVENTING AND/OR TREATING SIDE EFFECTS ASSOCIATED WITH ANTI-CANCER AGENTS USING NON-NATURALLY OCCURRING MELANOCORTIN ANALOGS WITH ANTI-GDF-15 ANTIBODIES | Endevica Bio, Inc. (US) | 2025-12-24 | — | — | EP | claimed |
| EP-4659591-A1 | TASTE-ENHANCING COMPOSITION, METHOD FOR PRODUCING SAME, FOOD PRODUCT, AND METHOD FOR ENHANCING TASTE OF FOOD PRODUCT | House Foods Group Inc. (JP) | 2025-12-10 | — | — | EP | claimed |
| US-12454551-B2 | Peptides as inhibitors of fibrotic matrix accumulation | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2025-10-28 | — | — | US | claimed |
| CN-112423774-A | Therapeutic compositions and methods of use for treating mild cognitive impairment, depression and psychological disorders | L·H·L·特兰 | 2021-02-26 | — | — | CN | claimed |
| US-10890592-B2 | Automated sample quality assessment | METABOLON, INC. (US) | 2021-01-12 | — | — | US | claimed |
| CN-106262576-B | Salty taste enhancer | 长谷川香料株式会社 | 2020-03-27 | — | — | CN | claimed |
| WO-2017189528-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | Ecolab USA, Inc. (US) | 2017-11-02 | — | — | WO | claimed |
| US-20170306504-A1 | CORROSION INHIBITOR COMPOSITIONS AND METHODS OF USING SAME | CHAMPIONX LLC | 2017-10-26 | — | — | US | claimed |
| EP-2828257-B1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD (GB) | 2017-07-26 | — | — | EP | claimed |
| US-20160374380-A1 | SALTY TASTE ENHANCER | T. HASEGAWA CO., LTD. (JP) | 2016-12-29 | — | — | US | claimed |
| EP-2398774-A2 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | Incyte Corporation (US) | 2011-12-28 | — | — | EP | claimed |
| US-20100190981-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION | 2010-07-29 | — | — | US | claimed |
| WO-2010083283-A2 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | INCYTE CORPORATION (US) | 2010-07-22 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12454551-B2 | Peptides as inhibitors of fibrotic matrix accumulation | GLS, AGXT, FN1 | PRCP 1729/4885TERT 4495/4885HTR2C 4763/4885 |
| US-20260098072-A1 | METHODS OF STIMULATING APPETITE AND/OR INCREASING BODY WEIGHT USING NON-NATURALLY OCCURRING MELANOCORTIN RECEPTOR ANTAGONIST ANALOGS | MC1R, MC4R, MC5R | PRCP 706/4885TERT 2870/4885HTR2C 1781/4885 |
| US-12584924-B2 | Compositions and methods for diagnosing and treating chronic kidney disease | GLS, AADAT, FGF23 | PRCP 254/4885TERT 3737/4885HTR2C 1620/4885 |
| US-20100190981-A1 | PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS | JAK3, JAK1, JAK2 | PRCP 2142/4885TERT 2350/4885HTR2C 2839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.